Drugs / TAK-128
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00756041 | Sep 2005 → Sep 2006 | diabetic neuropathy | Takeda | Terminated | No outcome recorded |
| Phase 2 | NCT00229437 | Mar 2005 → May 2006 | diabetic neuropathy | Takeda | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TAK-128 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00229437 ↗ |
| Route | Oral | “TAK-128 5 mg, tablets, orally, once daily for up to 6 months.” NCT00229437 ↗ |